Abstract
The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453–459.
| Original language | English |
|---|---|
| Pages (from-to) | 453-459 |
| Number of pages | 7 |
| Journal | Annals of neurology |
| Volume | 96 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2024 |
Fingerprint
Dive into the research topics of 'Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver